Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Pharm Res. 2015 Apr 4;32(9):3029–3043. doi: 10.1007/s11095-015-1684-4

Figure 7.

Figure 7

Western blot data in (A) and (B) reveal that VEGF expression was 42.9% lower in the bumetanide-treated tumors than in the control tumors after 3 weeks of therapy (p=0.021). The IHC images in (C) support this result and show that, much like CD31, a decrease in VEGF expression (red) is associated with greater levels of hypoxia (green).